Neuren Pharmaceuticals (ASX:NEU) Shares Rise on Upgraded Guidance

Sonal Goyal

05 November 2026 01:00 PM AEDT

Neuren Pharmaceuticals (ASX:NEU) Shares Rise on Upgraded Guidance

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Neuren Pharmaceuticals shares were priced at $23.10 during the 5 November 2026 trading session, up 16.79%.
A release dated 5 November 2026 increased 2026 total income guidance from trofinetide to US$91 to 93 million, from US$53 to 56 million.
Q3 2026 DAYBUE net sales were US$140 million, up 39% on Q3 2025.

Neuren Pharmaceuticals Ltd (ASX:NEU) shares were priced at $23.10 during the Trading session on 5 November 2026, up 16.79%. The S&P/ASX 200 was up 1.88%, or 166.10 points, at 9,000.60 at around 12:15 pm Sydney time, so the broader market was also trading higher during the session. Neuren is a neuroscience company with Royalty income from trofinetide, sold as DAYBUE by Acadia. Its latest update, dated 5 November 2026, covers third-quarter sales and an upgrade to its full-year guidance.

Latest Development: Q3 2026 Update (5 November 2026)

In an ASX announcement dated 5 November 2026, Neuren said Q3 2026 DAYBUE net sales were US$140 million, up 39% from Q3 2025, driven by uptake of DAYBUE STIX. The company earned Q3 royalty income of US$16.4 million, up 51% from a year earlier.

Neuren increased its 2026 total income guidance from trofinetide, including royalties and milestone payments, to US$91 to 93 million. The company also earned a US$35 million milestone payment on the launch of DAYBUE in Germany in October 2026. Acadia raised its full-year global net sales guidance to US$505 to 520 million, which implies Neuren royalty income of US$56 to 58 million.

Sector Context

The health care sector was up 2.86% in the session, a broad move that sits alongside the company's own news flow. Rare disease therapies are often assessed on launch uptake and on the pace of new country approvals.

What to Watch Ahead

Investors may track the Japanese regulatory submission planned for 2027 and the potential launch in 2028, subject to approval, along with Acadia's quarterly sales updates.

Key Risks

Royalty income depends on sales by Acadia, which can change with competition, reimbursement and patient numbers. Regulatory approvals in Japan are not assured. Guidance figures are forecasts.

Final Word

Neuren shares rose in the session, and the company's latest release lifted its 2026 income outlook and reported higher quarterly sales. Acadia's future updates will show how the sales trend develops.

FAQs

Q: How did Neuren shares trade on 5 November 2026?

A: NEU shares were priced at $23.10 during the trading session, up 16.79%, while the S&P/ASX 200 was also up at midday.

Q: What guidance was upgraded?

A: Neuren raised its 2026 total income guidance from trofinetide to US$91 to 93 million, from US$53 to 56 million.

Q: When could Japan launch occur?

A: The company said Japan trial results support a planned regulatory submission in 2027, with a potential launch in 2028 subject to approval.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.